New drug cocktail shows promise against tough esophageal cancer
NCT ID NCT07533305
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (QL1706 plus chemotherapy) as the first treatment for people with advanced or spreading esophageal cancer. About 50 adults who have not had prior treatment will receive the combo to see if it shrinks tumors and how long it keeps the cancer from growing. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- New drug duo aims to wipe out esophageal tumors before surgery
- Empowerment program aims to ease breast cancer treatment stress
- Could a drug combo let some esophageal cancer patients skip surgery?
- New triple therapy hopes to outsmart tough esophageal cancer